SENATE BILL No. 200 - Pharmacist Scope Expansion and Therapy Protocols

Sep 29, 2026

Uploaded by Miles

Kansas Senate Bill No. 200 amends the Kansas pharmacy act to expand pharmacists’ scope of practice. It allows pharmacists, under a statewide protocol, to initiate therapy for specified health conditions such as influenza, streptococcal pharyngitis, and urinary tract infection. The bill also updates K.S.A. 65-1626a and addresses collaborative drug therapy management, including protocol adoption considerations based on patient age, FDA approval, in-person interactions, and administration method.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages4

Reading Time10 min

AccessFree to download

Overview

Expanded pharmacist therapy scope

Statewide protocol and advisory committee considerations

Amendments to K.S.A. 65-1626a

As Amended by Senate Committee Session of 2021 SENATE BILL No. 200 By Committee on Public Health and Welfare 2-10 1 AN ACT concerning pharmacists and pharmacy; relating to the state board 2 of pharmacy; expanding the pharmacist's scope of practice to include 3 point-of-care testing for and treatment of certain health conditions; 4 amending K.S.A. 65-1626a and repealing the existing section. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 ~~New Section 1. A pharmacist may independently test or screen for~~ 8 ~~ and initiate therapy pursuant to a state-wide protocol established by the~~ 9 ~~ state board of pharmacy for health conditions of individuals who are ~~10 ~~ eligible to receive the testing or screening service~~.~~ For purposes of this ~~11 ~~ section, a health condition is a condition that is generally managed with ~~12 ~~minimal treatment or self-care and includes~~,~~ but is not limited to:~~ 13 ~~ (a) Influenza;~~ 14 ~~ (b) streptococcus;~~ 15 ~~ (c) COVID-19;~~ 16 ~~ (d) pre-exposure prophylaxis; ~~ 17 ~~ (e) post-exposure prophylaxis; or~~ 18 ~~ (f) a condition for which its diagnostic test is waived under the ~~ 19 ~~ federal clinical laboratory improvement amendments of 1988.~~ 20 New Section 1. (a) A pharmacist may initiate therapy within the 21 framework of a statewide protocol for the following health conditions: 22 (1) Influenza; 23 (2) streptococcal pharyngitis; or 24 (3) urinary tract infection. 25 (b) The collaborative drug therapy management advisory committee 26 may adopt a statewide protocol for each condition listed in subsection 27 (a). The committee shall consider appropriateness of therapy based 28 upon: 29 (1) The patient's age; 30 (2) approval by the United States food and drug administration; 31 (3) in-person interactions; and 32 (4) the method of administration. 33 Sec. 2. K.S.A. 65-1626a is hereby amended to read as follows: 65- 34 1626a. (a) For the purpose of the pharmacy act of the state of Kansas, the 35 following~~ persons~~ individuals shall be deemed to be engaged in the 36 practice of pharmacy: SB 200—[Am. by](Am. by) SC 2 1 (1) ~~Persons~~Individuals who publicly profess to be a pharmacist, or 2 publicly profess to assume the duties incident to being a pharmacist and 3 their knowledge of drugs or drug actions, or both; and 4 (2) ~~persons~~individuals who attach to their name any words or 5 abbreviation indicating that they are a pharmacist licensed to practice 6 pharmacy in Kansas. 7 (b) As used in this section: 8 (1) "Practice of pharmacy" means: 9 (A) The interpretation and evaluation of prescription orders; 10 (B) the compounding, dispensing and labeling of drugs and devices 11 pursuant to prescription orders; 12 (C) the administering of vaccine pursuant to a vaccination protocol; 13 (D) the participation in drug selection according to state law and 14 participation in drug utilization reviews; 15 (E) the proper and safe storage of prescription drugs and prescription 16 devices and the maintenance of proper records thereof in accordance with 17 law; 18 (F) consultation with patients and other health care practitioners 19 about the safe and effective use of prescription drugs and prescription 20 devices; 21 (G) performance of collaborative drug therapy management pursuant 22 to a written collaborative practice agreement with one or more physicians 23 who have an established physician-patient relationship;~~ and~~ 24 (H) participation in the offering or performing of those acts, services, 25 operations or transactions necessary in the conduct, operation, 26 management and control of a pharmacy; and 27 (I) ~~ the initiation of drugs~~,~~ drug categories or devices that are~~ ~~ ~~ 28 ~~ initiated in accordance with the product~~'~~s federal food and drug ~~29 ~~ administration-approved labeling and limited to conditions listed below~~ ~~ ~~ 30 ~~ that:~~ 31

FAQs

What does Senate Bill No. 200 change about pharmacists’ scope of practice in Kansas?

It expands pharmacists’ authority to initiate therapy within a statewide protocol for specified health conditions, and it amends K.S.A. 65-1626a accordingly.

Which health conditions does the bill authorize pharmacists to initiate therapy for under the statewide protocol?

The bill lists influenza, streptococcal pharyngitis, and urinary tract infection.

How is a statewide protocol for each condition adopted and what factors must be considered?

A collaborative drug therapy management advisory committee may adopt protocols for listed conditions and must consider therapy appropriateness based on the patient’s age, FDA approval, in-person interactions, and the method of administration.

Sep 29, 2026

Uploaded by Miles